Home>Topics>Industry>Biotechnology Industry

Biotechnology Industry

  1. All
  2. Stock Reports
  1. New Morningstar Analyst Report for Biomarin Pharmaceutical, Inc.

    Stock Reports

    Fri, 11 Apr 2014

    BioMarin's Vimizim should boost top-line growth and bring the firm to profitability.

  2. New Morningstar Analyst Report for Biogen Idec Inc

    Stock Reports

    Fri, 11 Apr 2014

    Biogen's wide moat is built in its MS dominance and strong midstage pipeline.

  3. New Morningstar Analyst Report for MannKind Corporation

    Stock Reports

    Wed, 2 Apr 2014

    MannKind's inhaled insulin could serve a sizable niche of the diabetes market.

  4. New Morningstar Analyst Report for Celgene Corporation

    Stock Reports

    Tue, 25 Mar 2014

    Celgene's Revlimid supports a narrow moat, but oncology and immunology drugs are diversifying sales.

  5. New Morningstar Analyst Report for Vanda Pharmaceuticals, Inc.

    Stock Reports

    Tue, 25 Mar 2014

    Given the rarity and limited awareness of non-24 disorder, it will be challenge for Vanda to build the market for the drug.Fanapt's uptake has been limited by its lack of meaningful comparative effectiveness data with other antipsychotics, which may be limiting its market potential.Because of its

  6. New Morningstar Analyst Report for Gilead Sciences Inc

    Stock Reports

    Tue, 25 Mar 2014

    Gilead's HIV franchise provides three fourths of the firm's revenue. Heavy dependence on tenofovir, which loses exclusivity in 2018, puts pressure on Gilead's hepatitis C portfolio to support growth.Pricing pressure and reduced willingness to pay for convenience could weigh on Gilead's growth.

  7. New Morningstar Analyst Report for Grifols SA

    Stock Reports

    Tue, 18 Mar 2014

    Grifols' narrow moat stems from its scale and expertise in plasma protein processing.

  8. New Morningstar Analyst Report for Amgen Inc

    Stock Reports

    Tue, 18 Mar 2014

    Generic versions of Amgen's Epogen and Neupogen have entered the market in Europe. These biosimilars could have a larger impact in years to come, as patents expire and as a U.S. regulatory pathway for biosimilars is finalized.Clinical data has brought the safety of the entire ESA class of drugs

  9. New Morningstar Analyst Report for Alexion Pharmaceuticals, Inc.

    Stock Reports

    Tue, 11 Mar 2014

    Soliris franchise expansion and progress of orphan-focused pipeline add depth to ALXN’s narrow moat.

  10. New Morningstar Analyst Report for Anheuser-Busch Inbev SA

    Stock Reports

    Mon, 24 Feb 2014

    The company's flagship Budweiser brand is facing meaningful headwinds in the United States from craft brewers, spirits companies, and persistently high levels of unemployment.The European beer market is much more fragmented than that of the Americas, and significant retailer and pub consolidation

« Prev12345Next »
Content Partners